Umoja Biopharma | $100,000,000 | (Jan 21, 2025)
Fundment | $55,157,175 | (Jan 21, 2025)
r4 | $1,000,000 | (Jan 21, 2025)
Certified by Founder
Lodge
Crossbow Therapeutics, Inc
start up
United States
- Cambridge, MA
- 12/07/2023
- Series A
- $80,000,000
Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company’s T-Bolt™ therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow’s efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer.
- Industry Biotechnology Research
- Website https://www.crossbowtx.com/
- LinkedIn https://www.linkedin.com/company/crossbow-therapeutics-inc/
IntusCare | $11,500,000 | (Jan 21, 2025)
Alteva Technologies | $1,760,526 | (Jan 21, 2025)
ecoplanet | $16,571,680 | (Jan 21, 2025)
StepChange.work | $4,000,000 | (Jan 21, 2025)
Sereact | $25,894,660 | (Jan 21, 2025)
Men In Blazers Media Network | $150,000,000 | (Jan 21, 2025)
Pipe17 | $15,500,000 | (Jan 17, 2025)
Coram AI | $13,800,000 | (Jan 17, 2025)
Quantifind | $22,000,000 | (Jan 17, 2025)